Mexican fish treatment companies have raised the prices of their therapeutic fish treatment products by $1.3 million to $2.2 million per session in the past two years, according to an investigation by the Associated Press.
The price increases have come on top of a $1 billion dollar cost-cutting spree the companies announced last year.
The cost increases come on the heels of the company announcing it would close its $8.3 billion ($1.6 billion) pet food business by 2019.
The prices are so high, they’re going to cost you a lot of money,” said Carlos Sánchez, the director of operations at Pet Therapy Inc., a private company that has treated more than 300,000 people and has $10 million in total revenue.”
The price increases come at a time when many patients are facing financial pressures. “
If you are not getting the quality of treatment that you are paying, I don’t know what to tell you.”
The price increases come at a time when many patients are facing financial pressures.
The federal government cut the number of doctors by nearly a quarter in the last year to just 2,000, and the number has fallen by one-third since then.
A lack of money to pay bills also makes it more difficult for people to find care, which can lead to health problems.
For more than a decade, the U.S. Fish and Wildlife Service has been reviewing fish therapy treatments for people with certain medical conditions.
Many of those conditions include chronic kidney disease, diabetes, and arthritis, according the AP.
Some experts say that the price hikes are unfair because many of the treatments also treat other conditions, such as arthritis.
In addition, some of the therapies have been around for decades and the FDA hasn’t changed the rules in the way that they are administered.
“We know fish therapy is the best treatment for the conditions that it is,” said Dr. Scott Smith, an internist at the University of Florida.
“We are just trying to find the best way to do that.”
The FDA has made fish therapy a priority for its efforts to reduce opioid addiction and deaths in the U, and has said it is considering expanding its oversight of the drug industry.
The agency has said that the FDA will review all fish therapy products made by private companies, as well as those manufactured by the U and FDA-approved distributors.